EquitySector - HealthcareVery High Risk
Regular
NAV (20-Dec-24)
Returns (Since Inception)
Fund Size
₹1,214 Cr
Expense Ratio
2.14%
ISIN
INF277K016A9
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+42.34%
+43.28% (Cat Avg.)
3 Years
+22.77%
+21.60% (Cat Avg.)
5 Years
+27.39%
+27.61% (Cat Avg.)
Since Inception
+13.35%
— (Cat Avg.)
Equity | ₹1,161.93 Cr | 95.72% |
Others | ₹52 Cr | 4.28% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹148.71 Cr | 12.31% |
Aurobindo Pharma Ltd | Equity | ₹103.48 Cr | 8.57% |
Lupin Ltd | Equity | ₹89.72 Cr | 7.43% |
Dr Reddy's Laboratories Ltd | Equity | ₹78.31 Cr | 6.48% |
Cipla Ltd | Equity | ₹76.04 Cr | 6.29% |
Cash / Net Current Asset | Cash | ₹63.1 Cr | 5.22% |
Divi's Laboratories Ltd | Equity | ₹61.82 Cr | 5.12% |
Fortis Healthcare Ltd | Equity | ₹53.42 Cr | 4.42% |
Zydus Lifesciences Ltd | Equity | ₹47.19 Cr | 3.91% |
Alkem Laboratories Ltd | Equity | ₹43.49 Cr | 3.60% |
Apollo Hospitals Enterprise Ltd | Equity | ₹41.37 Cr | 3.42% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹29.21 Cr | 2.42% |
Ajanta Pharma Ltd | Equity | ₹29.03 Cr | 2.40% |
Medi Assist Healthcare Services Ltd | Equity | ₹25.85 Cr | 2.14% |
FDC Ltd | Equity | ₹25.76 Cr | 2.13% |
Orchid Pharma Ltd | Equity | ₹25.51 Cr | 2.11% |
HealthCare Global Enterprises Ltd | Equity | ₹25.47 Cr | 2.11% |
Wockhardt Ltd | Equity | ₹23.37 Cr | 1.93% |
Torrent Pharmaceuticals Ltd | Equity | ₹22.71 Cr | 1.88% |
Ipca Laboratories Ltd | Equity | ₹22.63 Cr | 1.87% |
Indoco Remedies Ltd | Equity | ₹20.7 Cr | 1.71% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹16.11 Cr | 1.33% |
Piramal Pharma Ltd | Equity | ₹16.02 Cr | 1.33% |
Jupiter Life Line Hospitals Ltd | Equity | ₹14.31 Cr | 1.18% |
Sanofi India Ltd | Equity | ₹13.02 Cr | 1.08% |
Laurus Labs Ltd | Equity | ₹12.53 Cr | 1.04% |
Mankind Pharma Ltd | Equity | ₹11.06 Cr | 0.92% |
Coromandel International Ltd | Equity | ₹10.01 Cr | 0.83% |
Ami Organics Ltd | Equity | ₹9.89 Cr | 0.82% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹9.44 Cr | 0.78% |
Syngene International Ltd | Equity | ₹9.21 Cr | 0.76% |
Procter & Gamble Health Ltd | Equity | ₹8.37 Cr | 0.69% |
Medplus Health Services Ltd | Equity | ₹7.92 Cr | 0.66% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.67 Cr | 0.55% |
Deepak Nitrite Ltd | Equity | ₹4.72 Cr | 0.39% |
A) Repo | Cash - Repurchase Agreement | ₹1.89 Cr | 0.16% |
Large Cap Stocks
39.30%
Mid Cap Stocks
29.56%
Small Cap Stocks
24.82%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,118.43 Cr | 92.58% |
Basic Materials | ₹24.62 Cr | 2.04% |
Standard Deviation
This fund
15.14%
Cat. avg.
15.68%
Lower the better
Sharpe Ratio
This fund
0.91
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since March 2021
Since September 2024
ISIN INF277K016A9 | Expense Ratio 2.14% | Exit Load No Charges | Fund Size ₹1,214 Cr | Age 8 years 11 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹32.33 Cr | 47.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹854.32 Cr | 39.5% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹854.32 Cr | 37.6% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹42.05 Cr | 43.4% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹217.92 Cr | 47.7% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹217.92 Cr | 44.9% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2742.91 Cr | 43.0% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2742.91 Cr | 40.9% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹840.57 Cr | 40.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.39 Cr | 42.4% |
Total AUM
₹1,88,167 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Your principal amount will be at Very High Risk